Gilead Sciences | Srodki Pieniężne I Ekwiwalent



Cash And Equivalent Zmiana Data
AbbVie USD 5.52B 1.73B 2024-12
Agios Pharmaceuticals USD 78.96M 2.72M 2025-03
ALKERMES USD 399.81M 108.66M 2025-03
Alnylam Pharmaceuticals USD 1.02B 53.23M 2025-03
Amgen USD 8.81B 3.16B 2025-03
Biogen USD 2.6B 223.3M 2025-03
BioMarin Pharmaceutical USD 612.03M 1.19M 2025-03
Bristol-Myers Squibb USD 10.88B 529M 2025-03
Eli Lilly USD 3.09B 175.1M 2025-03
Gilead Sciences USD 7.93B 2.06B 2025-03
GlaxoSmithKline GBP 4.46B 594M 2025-03
Glaxosmithkline GBP 3.87B 678M 2024-12
Incyte USD 2.41B 720.83M 2025-03
J&J USD 38.47B 32.35B 2025-03
Merck USD 8.63B 4.61B 2025-03
Moderna USD 1.62B 304M 2025-03
Neurocrine Biosciences USD 233M 116.1M 2024-12
Novartis USD 8.87B 4.74B 2024-12
Pfizer USD 1.43B 387M 2025-03
PTC Therapeutics USD 2.03B 1.25B 2025-03
Regeneron Pharmaceuticals USD 3.09B 14.82B 2025-03
Sanofi 7.99B 550M 2025-03
Sarepta Therapeutics USD 240.87M 862.14M 2025-03
United Therapeutics USD 1.9B 202.7M 2025-03
Vertex Pharmaceuticals USD 4.57B 669.6M 2024-12



Gilead Sciences Srodki Pieniężne I Ekwiwalent - Aktualne wartości, dane historyczne, prognozy, statystyki, wykresy i kalendarz ekonomiczny - May 2025.